Lv1
20 积分 2025-05-17 加入
A first-in-class JAK/ROCK inhibitor, Rovadicitinib in patients with myelofibrosis who were refractory or relapsed or intolerant to Ruxolitinib: A single-arm, multicenter, open-label, phase Ib study
1天前
已完结
JAK2 V617F as a diagnostic and prognostic biomarker in myeloproliferative neoplasms
1天前
求助中
[Expert consensus on the application of rituximab in the treatment of membranous nephropathy]
1个月前
已完结
[Clinical practice guidelines for adult patients with IgA nephropathy and IgA vasculitis-associated nephritis in China (2025)]
2个月前
已完结
High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma
3个月前
已完结
Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies
4个月前
已完结
Characteristics and outcomes of non-transplanted newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, lenalidomide, dexamethasone (DVRd) with once-weekly bortezomib dosing
4个月前
已关闭
Therapeutic milestones against multidrug resistant Acinetobacter baumannii: from legacy antibiotics to Zosurabalpin
4个月前
已完结
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature
4个月前
已完结
Autologous Stem Cell Transplantation in Multiple Myeloma: Is It Still the Gold Standard?
4个月前
已关闭
皖公网安备34019202002308
